Milton Keynes University Hospital NHS
NHS Foundation Trust

Standing Way
Eaglestone
Milton Keynes
MK6 5LD
Tel: 01908 660033
www.mkhospital.nhs.uk
For people who have hearing loss
Minicom 01908 243924

Ref: 02756_03861_2018-01-18_01
Date: 18 January 2018

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 03 January 2018.

I am pleased to confirm the following.

1. **Do you test newly diagnosed bowel cancer patients in your trust (either contracted or referred) for molecular features of Lynch syndrome using either immunohistochemistry or microsatellite instability testing?**

   - Yes – all bowel cancer patients, as per DG 27 NICE guidance
   - Yes - everyone under the age of 70
   - Yes – everyone under the age of 50
   - Yes – according to family history of the disease
   - No
   - **Other (patients under 50 years at time of diagnosis and for patients, in whom an assessment of prognosis is appropriate, with adenocarcinomas classified as poorly differentiated morphologically or tumours showing other morphological features of MMR deficiency.)-based on previous RCPath recommendation(2014)***
   - **The current recommendation is to provide MMR to all patients with colorectal carcinoma however, and it is decided that this will be reviewed at Trust level, with respect to funding.**

2. **If yes, at what stage does this testing take place?**

   - Pre-treatment i.e. at diagnosis (on a biopsy of the tumour)
   - **Post treatment i.e. test is carried out on the tumour resection specimen only.**
   - Not applicable

3. **Is this test carried out as a reflex test i.e. automatically or upon referral?**

   - Reflex
   - Referral via MDT
   - Referral via Genetics Centre
   - Referral via GP
   - Other (please explain)
   - **Not applicable**

4. **In their published adoption support resource NICE suggest identifying a named 'clinical champion' within each colorectal multidisciplinary team to effectively implement testing people for molecular features for Lynch syndrome. Is this established in your trust?**

   - Yes, Gastroenterologist
   - Yes, Colorectal Surgeon
   - Yes, Oncologist
   - Yes, Clinical Geneticist
   - Other (please explain)
   - **No**

5. **Do you audit diagnostic outcomes within your trust to ensure that every patient is tested for molecular features for Lynch syndrome?**

   - Yes, as part of private audit
   - Yes, and the data is publicly released
   - **No**

6. **Have you had to submit a business case for funding in order to effectively implement this new guidance?**

   - Yes, and additional funding was provided fully/partially as requested. Please provide information.
   - Yes, but no additional funding was provided. Please provide information on why.
   - **No please provide information on why.**

7. **If no such testing is in place, do you have information on whether there are any plans to introduce molecular testing for Lynch syndrome as per NICE guidance?**

   We are currently reviewing the process

8. **What are the main barriers you have faced if no molecular testing or only selected testing is performed? Please specify.**

   - Financial
   - Policy
   - Awareness of current guidance
   - **Staff resources**
   - Other (please specify)

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom Of Information Co-ordinator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust